Publications
Could the properties of IL-27 make it an ideal adjuvant for anticancer immunotherapy?
Abstract
We have recently been the first to demonstrate that interleukin (IL)-27 protects against the emergence and progression of autochthonous tumors. Accumulating evidence suggests that IL-27 might be uniquely well positioned to amplify beneficial TH1 anticancer immune responses while suppressing the unwanted accumulation of regulatory T cells.
| Type | Journal |
|---|---|
| ISBN | 2162-4011 (Print) |
| Authors | Swarbrick, A.; Junankar, S. R.; Batten, M.; |
| Responsible Garvan Author | Professor Alexander Swarbrick |
| Publisher Name | Oncoimmunology |
| Published Date | 2013-08-01 |
| Published Volume | 2 |
| Published Issue | 8 |
| Published Pages | e25409 |
| Status | Published in-print |
| URL link to publisher's version | http://www.ncbi.nlm.nih.gov/pubmed/24083081 |
| OpenAccess link to author's accepted manuscript version | https://publications.gimr.garvan.org.au/open-access/11889 |